Compare · MDT vs ZYXI
MDT vs ZYXI
Side-by-side comparison of Medtronic plc. (MDT) and Zynex Inc. (ZYXI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and ZYXI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $106.97B, about 361.0x ZYXI ($296.3M).
- Over the past year, MDT is down 0.8% and ZYXI is down 94.1% - MDT leads by 93.3 points.
- MDT has hit the wire 6 times in the past 4 weeks while ZYXI has been quiet.
- MDT has more recent analyst coverage (25 ratings vs 10 for ZYXI).
- Company
- Medtronic plc.
- Zynex Inc.
- Price
- $83.32-0.55%
- $0.13-31.48%
- Market cap
- $106.97B
- $296.3M
- 1M return
- -5.21%
- -77.93%
- 1Y return
- -0.81%
- -94.10%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 10
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Zynex Inc.
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES) device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. The company also supplies electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products; and distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers CM-1500, a blood volume monitor device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Latest MDT
- Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues
- Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
- Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease
- The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
- Medtronic to announce financial results for its fourth quarter and full fiscal year 2026
- Telix Strengthens Board with Additional Director Appointments
- Amendment: SEC Form SCHEDULE 13G/A filed by Medtronic plc.
- Medtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT Procedures
- Medtronic plc. filed SEC Form 8-K: Regulation FD Disclosure
- Medtronic OmniaSecure™ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing
Latest ZYXI
- Zynex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Zynex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
- Zynex Financial Restructuring Puts Company on Path to Long-Term Success
- SEC Form 3 filed by new insider Aronzon Paul
- SEC Form 10-Q filed by Zynex Inc.
- Zynex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zynex Reports Third Quarter 2025 Financial Results
- Zynex Announces Strategic Initiatives: Engagement of Province, Appointment of Paul Aronzon to Board of Directors, and Formation of Special Committee
- Zynex Sets Third Quarter 2025 Earnings Call
- SEC Form NT 10-Q filed by Zynex Inc.